NCT05807542

Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC

Prediction for pCR After Neoadjuvant Immunotherapy Combined With Chemotherapy Using Single-Cell RNA Sequencing in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC) : A Single-Arm Phase II Clinical Trial

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Shanghai Zhongshan Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Prediction for pCR After Neoadjuvant Immunotherapy Combined With Chemotherapy Using Single-Cell RNA Sequencing in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma

Conditions

• Esophagus Cancer

Interventions

Type	Name	Description
DRUG	Tislelizumab	Tislelizumab will be administered on day 1 of each cycle at 200mg once every 21 days.
DRUG	Paclitaxel-albumin	Paclitaxel-albumin will be administered on day 1 of each cycle at 260mg/m2 once every 21 days.
DRUG	Carboplatin	carboplatin will be administered on day 1 of each cycle at AUC=5 once every 21 days.

Timeline

• Start date: 2022-03-01
• Primary completion: 2023-09-30
• Completion: 2024-04-30
• First posted: 2023-04-11
• Last updated: 2024-05-16

Locations

1 site across 1 country: China